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Abstract
EHMT2 is a histone lysine methyltransferase localized in euchromatin regions and acting as a corepressor for specific
transcription factors. Although the role of EHMT2 in transcriptional regulation has been well documented, the patho-
logic consequences of its dysfunction in human disease have not been well understood. Here, we describe impor-
tant roles of EHMT2 in human carcinogenesis. Expression levels of EHMT2 are significantly elevated in human bladder
carcinomas compared with nonneoplastic bladder tissues (P< .0001) in real-time polymerase chain reaction analysis.
Complementary DNA microarray analysis also revealed its overexpression in various types of cancer. The reduction
of EHMT2 expression by small interfering RNAs resulted in the suppression of the growth of cancer cells and pos-
sibly caused apoptotic cell death in cancer cells. Importantly, we show that EHMT2 can suppress transcription of the
SIAH1 gene by binding to its promoter region (−293 to +51) and by methylating lysine 9 of histone H3. Furthermore,
an EHMT2-specific inhibitor, BIX-01294, significantly suppressed the growth of cancer cells. Our results suggest that
dysregulation of EHMT2 plays an important role in the growth regulation of cancer cells, and further functional studies
may affirm the importance of EHMT2 as a promising therapeutic target for various types of cancer.
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Introduction
Histone methylation plays dynamic and crucial roles in regulating
chromatin structure. Precise coordination and organization of open
and closed chromatin regions control normal cellular processes such
as DNA replication, repair, recombination, and transcription. Histone
lysine methylation is considered to regulate the transcription positively
or negatively depending on the methylation sites and the methylation
status [1]. For instance, methylation of histone H3 at lysine 9 (H3K9)
has served as the prototype for studying the regulation of histone func-
tion by lysine methylation. Dimethylation or trimethylation of H3K9
creates a binding site for chromodomain-containing proteins of the
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heterochromatin protein 1 family [2,3], which is speculated to lead to
gene repression through changes in higher-order chromatin structure.
Methylation-dependent heterochromatin protein 1 recruitment can
be antagonized by adjacent H3 serine 10 phosphorylation. Thus, his-
tones are subject to a system of combinatorially acting posttranslational
modifications, referred to as the “histone code” [4–6]. Despite a large
body of information for the prominent role of histone methylation
in transcriptional regulation, their physiological function and their
involvement in human disease are still not well understood. We pre-
viously reported that the histone methyltransferase SMYD3 stimulates
cell proliferation through its methyltransferase activity and plays a cru-
cial role in human carcinogenesis [7,8], and several groups also showed
that deregulation of histone methyltransferases could be involved in
human carcinogenesis [9,10]. To find other methyltransferases in-
volved in human carcinogenesis, we examined expression profiles for
a number of histone methyltransferases using clinical tissues and found
transactivation of EHMT2 in nine types of tumors, including bladder
and lung cancers.
EHMT2, also known as G9a, is mainly responsible for mono-
methylation and dimethylation of H3K9 in euchromatin [11]. EHMT2
is essential for early embryonic development and is involved in the
transcriptional silencing of developmentally regulated genes. Knockout
of EHMT2 causes embryonic lethality in mice, indicating a major role
for epigenetic repression in early mammalian development [12]. Previ-
ous studies found that EHMT2 functions as a corepressor, targeted to
specific genes by associating with various transcriptional repressors and
corepressors: CDP/Cut, Blimp-1/PRDI-BF1, and REST/NRSF [13–
15]. Meanwhile, EHMT2 also seems to function as a coactivator for
nuclear receptors, collaborating synergistically with CARM1 and other
nuclear receptor coactivators [16]. In addition, the complex of EHMT2
and DNMT1 led to enhanced DNA and histone methylation of
in vitro assembled chromatin substrates, indicating that direct co-
operation between EHMT2 and DNMT1 provides a mechanism of
H3K9 methylation and coordinated DNA during cell division [17].
SIAH (seven in absentia homolog) proteins are members of the
RING-finger-containing E3 ubiquitin ligases. They are homologs
of the Drosophila seven in absentia (Sina) protein [18,19]. It has been
suggested that the SIAH1 protein plays a key role in biologic processes
such as the cell cycle, cell apoptosis, and oncogenesis [20–22]. Here, we
demonstrate the possible involvement of EHMT2 in human carcino-
genesis and direct transcriptional regulation of SIAH1 by EHMT2.
These results imply that EHMT2 is a candidate therapeutic target
for various types of cancer.
Materials and Methods
Cell Culture
Cancer cell lines used in this study were as follows: lung adeno-
carcinoma = LC319 and A549; lung squamous cell carcinoma =H2170,
RERF-LC-AI; small cell lung cancer = SBC-5; bladder cancer = 5637,
253J, 253JBV, EJ28, HT1197, HT1376, J82, RT4, SCaBER,
SW780, T24, and UMUC3. The normal human lung fibroblast HFL-1
and the normal human colon fibroblast CCD-18Cowere used as normal
control cells. All cell lines were grown in monolayers in appropriate me-
dia: Dulbecco modified Eagle medium for EJ28, RERF-LC-AI, and
293T cells; Eagle minimal essential medium for CCD-18Co, 253J,
IMR90,WI38, 253J-BV,HT1197,HT1376, J82, SCaBER,UMUC3,
and SBC5 cells; F-12K medium for HFL-1 cells; Leibovitz L-15 for
SW780 cells; McCoy 5A medium for RT4 and T24 cells; RPMI-
1640 medium for 5637, A549, H2170, and LC319 cells supplemented
with 10% fetal bovine serum and 1% antibiotic/antimycotic solution
(Sigma-Aldrich, St Louis, MO). All cells were maintained at 37°C in
humid air with 5% CO2 condition (CCD-18Co, HFL-1, IMR90,
WI38, H2170, 5637, 253J, 253J-BV, EJ28, HT1197, HT1376,
J82, RT4, SCaBER, T24, UMUC3, A549, LC319, RERF-LC-
AI, SBC5, and 293T) or without CO2 (SW780). Cells were transfected
with FuGENE6 (Roche Applied Science, Basel, Switzerland) according
to the manufacturer’s protocols.
Immunohistochemical Staining and Tissue Microarray
Immunohistochemical analysis was performed using a specific poly-
clonal rabbit-EHMT2 antibody as described previously [23,24]. For
clinical bladder tissue microarray, VECTASTAIN ABC Kit (Vector
Laboratories, Burlingame, CA) was applied. Briefly, endogenous per-
oxidase activity of xylene-deparaffinized and dehydrated sections was
inhibited by treatment with 0.3% H2O2/methanol. Nonspecific bind-
ing was blocked by incubating sections with 3% bovine serum albumin
in a humidified chamber for 30 minutes at ambient temperature, then a
1:1000 dilution of rabbit polyclonal anti-EHMT2 antibody (NB100-
40825; Novus Biologicals, Littleton, CO) overnight at 4°C. Sections
were washed twice with phosphate-buffered saline, incubated with
1 μg/μl goat antirabbit biotinylated IgG in phosphate-buffered sa-
line containing 1% bovine serum albumin for 30 minutes at ambient
temperature and then incubated with ABC reagent for 30 minutes.
Immunostaining was visualized using 3,3′-diaminobenzidine. Slides were
dehydrated through graded alcohol to xylene washing and mounted on
coverslips.Hematoxylin was used for nuclear counterstaining. For clinical
lung cancer tissue microarray, EnVision+ kit/horseradish peroxidase
(Dako, Glostrup, Denmark) was applied. Briefly, slides of paraffin-
embedded lung tumor specimens were processed under high pressure
(125°C for 30 seconds) in an antigen-retrieval solution, high pH 9
(S2367; Dako Cytomation, Carpinteria, CA), treated with peroxidase
blocking reagent, and then treated with a protein blocking reagent
(K130, X0909; Dako Cytomation). Tissue sections were incubated
with a rabbit anti-EHMT2 polyclonal antibody followed by HRP-
conjugated secondary antibody (Dako Cytomation). The antigen was
visualized with a substrate chromogen (Dako liquid DAB chromogen;
Dako Cytomation). Finally, tissue specimens were stained with Mayer
hematoxylin (Muto Pure Chemicals Ltd, Tokyo, Japan) for 20 seconds
to discriminate the nucleus from the cytoplasm.
Quantitative Real-time Polymerase Chain Reaction
As described previously, we obtained 118 bladder cancer tissues and
26 normal bladder tissues from Addenbrooke’s Hospital, Cambridge.
For quantitative reverse transcription–polymerase chain reactions (RT-
PCRs), specific primers for all human GAPDH (housekeeping gene),
SDH (housekeeping gene), and EHMT2 were designed (primer se-
quences in Table W5). PCRs were performed using the ABI Prism
7700 Sequence Detection System (Applied Biosystems, Warrington,
United Kingdom) following the manufacturer’s protocol. Moreover,
50% SYBR Green Universal PCR MasterMix without UNG (Applied
Biosystems), 50 nM each of the forward and reverse primers, and 2 μl
of reverse-transcribed complementary DNA (cDNA) were applied.
Amplification conditions were 5 minutes at 95°C and then 45 cycles
each consisting of 10 seconds at 95°C, 1 minute at 55°C, and 10 sec-
onds at 72°C. Then, reactions were heated for 15 seconds at 95°C,
1 minute at 65°C to draw the melting curve, and cooled to 50°C for
10 seconds. Reaction conditions for target gene amplification were as
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described previously, and the equivalent of 5 ng of reverse-transcribed
RNA was used in each reaction. Messenger RNA (mRNA) levels were
normalized to GAPDH and SDH expressions.
Small Interfering RNA Transfection
Small interfering RNA (siRNA) oligonucleotide duplexes were pur-
chased from SIGMA Genosys (St Louis, MO) for targeting the human
EHMT2 and SIAH1 transcripts. siEGFP, siFFLuc, and siNegative Con-
trol (siNC) were used as controls. siRNA sequences are described in
Table W2. siRNA duplexes (final concentration, 100 nM) were trans-
fected in lung cancer cell lines with Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) for 72 hours, and cell viability was examined using Cell
Counting Kit 8 (DOJINDO, Kumamoto, Japan).
Flow Cytometry Assays for Cell Cycle Analysis
We collected the cells after trypsin treatment, washed them twice with
1000 μl of assay buffer, and centrifuged for 5 minutes at 5000 rpm.
Cells were resuspended in 200 μl of assay buffer. One thousand micro-
liters of fixative buffer was added, and the samples were incubated at
room temperature for 1 hour. Finally, we added the propidium iodide
reagent and analyzed the cell cycle profiles by flow cytometry (LSR II;
BD Biosciences, Franklin Lakes, NJ). The proportion of each cell divi-
sion was calculated and analyzed using Student’s t test for significance.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed
using ChIP Assay Kit (Millipore, Billerica, MA) according to the manu-
facturer’s protocol. Briefly, the fragment of EHMT2 and chromatin
complexes was immunoprecipitated with anti-FLAG antibody 48 hours
after transfection with pCAGGS-n3FC (Mock) and pCAGGS-n3FC-
EHMT2 (3×FLAG-EHMT2) vectors. After the bound DNA frag-
ments to EHMT2were eluted, the amount was subjected to quantitative
real-time PCRs. Primer sequences are shown in Table W5.
Microarray Hybridization and Statistical Analysis for the
Clarification of Downstream Genes
Microarray analysis to identify downstream genes were done de-
scribed previously [25–27]. Briefly, purified total RNA was labeled and
hybridized onto Affymetrix GeneChip U133 Plus 2.0 oligonucleotide
arrays (Affymetrix, Santa Clara, CA) according to the manufacturer’s in-
structions. We performed a pathway analysis using the hypergeometric
distribution test, which calculates the probability of overlap between
the up/downregulated gene set and each GO category compared against
another gene list that is randomly sampled. We applied the test to the
identified up/downregulated genes to test whether they are signifi-
cantly enriched (false discovery rate≤ 0.05) in each category of “biologic
processes” (857 categories) as defined by the Gene Ontology database.
Results
EHMT2 Expression Is Upregulated in Clinical Cancer Tissues
To identify the histone methyltransferase involved in human carcino-
genesis, we examined the expression profile for several histone methyl-
transferase genes using six clinical bladder samples, and we found a
significant difference of EHMT2 gene expression between cancer and
normal tissues (data not shown). Consequently, we analyzed 118 bladder
cancer samples and 26 normal control samples (British) and found a
significant elevation of EHMT2 expression in tumor cells compared with
that in normal cells (P < .0001, Mann-Whitney U test) (Figure 1A and
Table W1). No statistical significance was observed in the expression
levels among cancer samples of different stages and grades (Figure 1B).
This suggests that EHMT2 expression was upregulated at an early stage
in bladder carcinogenesis and remained high in the advanced stages of
the disease. Subclassification of tumors according to metastasis status,
sex, smoking history, and recurrence status identified no significant
differences of EHMT2 expression levels (data not shown). We then ana-
lyzed the expression patterns of EHMT2 in 34 Japanese clinical bladder
cancer samples by cDNA microarray (Figure 1C and Table 1) and
confirmed a significant overexpression in bladder cancers of Japanese
patients (P < .0001, Mann-Whitney U test). Consistent with this,
expression levels of EHMT2 in 12 bladder cancer cell lines were sig-
nificantly higher than those in 2 normal human fibroblast cell lines
(Figure W1). To evaluate protein expression levels of EHMT2 in clini-
cal tissues, we performed immunohistochemical analysis using an anti-
EHMT2 specific antibody. This antibody strongly stained the nucleus
of various types of bladder cancer tissues, whereas signals in the normal
bladder tissue were weak (Figure 1D).
In addition to bladder tissues, we examined expression levels of
EHMT2 in lung tissues. cDNA microarray experiments showed that
the EHMT2 expression was highly elevated in lung tumor tissues com-
pared with corresponding nonneoplastic tissues (Figure 2A and Table 1),
and the overexpression of EHMT2 in lung cancer was also validated by
quantitative real-time PCR (Figure 2B). In addition, expression levels of
EHMT2 in four lung cancer cell lines were significantly higher than in
two normal human fibroblast cell lines (Figure 2C). We then examined
EHMT2 protein expression levels in lung tissue by immunohistochem-
istry (Figure 2D) and observed strong EHMT2 staining in the nucleus of
cancer tissues and weak staining in nonneoplastic tissues. Besides, we
examined the microarray expression analysis of a large number of clinical
samples derived from Japanese subjects and found that EHMT2 expres-
sion was also significantly upregulated in various types of cancer com-
pared with corresponding nonneoplastic tissues (Table 1). These data
indicate that EHMT2 may be involved in many types of human cancer.
Growth Regulation of Cancer Cells by EHMT2
To investigate the role of EHMT2 in human carcinogenesis, we
performed knockdown experiments using siRNAs against EHMT2
(siEHMT2 #1 and #2) and two control siRNAs (siEGFP and siNC)
(Table W2). We transfected these two independent EHMT2 siRNAs
into A549 and SBC5 cells, in which EHMT2 was highly expressed
(Figure 3A). EHMT2 expression in the transfected cells was signifi-
cantly suppressed at the mRNA level, in comparison with cells trans-
fected with control siRNAs at the mRNA level (Figure 3B). Using the
siRNAs, we performed the cell growth assay. We observed a significant
growth suppression of two bladder cancer cell lines (SW780 and RT4)
and three lung cancer cell lines (LC319, A549, and SBC5) after treat-
ment with two EHMT2 siRNAs, although no effect was observed
for control siRNAs (Figure 3C ). To further assess the mechanism of
growth suppression induced by the siRNA, we analyzed the cell cycle
status of cancer cells after treatment with siRNAs using flow cytome-
try stained with propidium iodide. The proportion of cancer cells in
the G1, S, and G2/M phases slightly decreased and that in the sub-G1
phase increased in a significant manner after treatment with two differ-
ent EHMT2 siRNAs (Figure 3D). These results suggest that EHMT2
plays a crucial role in cell cycle regulation of cancer cells and that apop-
tosis is induced after EHMT2 knockdown.
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SIAH1 Directly Regulated by EHMT2 Is a Key Regulator
of Cancer Cell Growth and Apoptosis
To define the mechanism by which EHMT2 regulates the cell
cycle and apoptosis, we identified target genes regulated by EHMT2
using microarray expression analysis. To clarify early responding genes
after knockdown of EHMT2, we isolated total RNA from SW780 and
A549 cells 24 hours after treatment with siEHMT2. The expression
profile of these cells was analyzed by Affymetrix’s HG-U133 Plus 2.0
Array in comparison with those treated with control siRNAs (siEGFP
and siFFLuc), and we identified a set of genes that were significantly
up/downregulated. The sub-G1 population of cancer cells was signifi-
cantly increased by knockdown of EHMT2, according to FACS analy-
sis (Figure 3D), so we hypothesized that EHMT2 could be associated
with the regulation of apoptosis in cancer cells. We identified a down-
stream gene for EHMT2, which was known to be involved in apoptotic
regulation in cancer cells, by microarray analysis. The expression of our
candidate, SIAH1, could indeed be regulated by EHMT2 (Figure 4,
A and B, left). Up-regulation of SIAH1 after treatment with siEHMT2
was confirmed by both quantitative real-time PCR and Western blot
(Figure 4B, right, and C ). To test whether EHMT2 transcriptionally
regulates the SIAH1 expression, we performed a ChIP assay. EHMT2
protein was highly enriched at the promoter region of SIAH1 after
transfection with a 3×FLAG-EHMT2 vector together with increased
Table 1. Expression of EHMT2 in Cancer Tissues Analyzed by cDNA Microarray*.
Tissue Type Case (n) Ratio (Tumor/Normal)
Count > 2 Count > 3 Count > 5
Acute myelogenous leukemia 55 26 (47.3%) 8 (14.5%) 1 (1.8%)
Bladder cancer 34 19 (55.9%) 11 (32.4%) 4 (11.8%)
Breast cancer 78 14 (17.9%) 4 (5.1%) 3 (3.8%)
Cervical Cancer 19 5 (26.3%) 1 (5.3%) 0 (0%)
Chronic myelogenous leukemia 77 46 (59.7%) 40 (51.9%) 19 (24.7%)
Esophageal cancer (SqCC) 64 23 (35.9%) 15 (23.4%) 7 (10.9%)
Non–small cell lung cancer 35 17 (48.6%) 11 (31.4%) 3 (8.6%)
Osteosarcoma 27 9 (33.3%) 4 (14.8%) 3 (11.1%)
Small cell lung cancer 15 11 (73.3%) 3 (20%) 1 (6.7%)
*We compared the signal intensity EHMT2 between tumor tissues and corresponding nonneoplastic
tissues derived from the same patient.
Figure 1. Elevated EHMT2 expression in bladder cancer. (A) EHMT2 gene expression in normal and tumor bladder tissues in British cases.
Expression levels of EHMT2were analyzed by quantitative real-time PCR, and the result is shown by box-whisker plot. Mann-WhitneyU test
was used for statistical analysis. (B) Statistical analysis of EHMT2 expression categorized by the histologic grade (left) and pathologic stage
(right) of bladder tumors. Expression levels of EHMT2 were analyzed by quantitative real-time PCR, and the result is shown by box-whisker
plot. Mann-Whitney U test was used for statistical analysis. NS indicates not significant. (C) Comparison of EHMT2 expression between
normal and tumor tissues in bladder cancer. Signal intensity of each sample was analyzed by cDNA microarray, and the result is shown by
box-whisker plot (median, 50% boxed). Mann-Whitney U test was used for the statistical analysis. (D) Tissue microarray images of bladder
tumors stained by standard immunohistochemistry for protein expression of EHMT2. Clinical information for each section is represented
above the histologic pictures. Original magnification, ×200.
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levels of dimethylation on histone H3-K9 (Figure 4D). In addition,
to validate the function of endogenous EHMT2 protein in cancer cells,
we performed ChIP analysis of cells after treatment with EHMT2
siRNA, using anti-EHMT2 and -H3K9me2 antibodies. These data
showed that the siRNA treatment clearly diminished the binding of
endogenous EHMT2 to the promoter region of SIAH1 and reduced
H3K9 dimethylation in the region (Figure 4E ). Therefore, endoge-
nous EHMT2 protein can bind to the promoter region of SIAH1
and, through dimethylation of histone H3-K9, affect the regulation of
gene expression.
We then tried to clarify the significance of SIAH1 suppressed by
EHMT2 in cancer cells. Because knockdown of EHMT2 significantly
increased the sub-G1 population of cancer cells, we performed detailed
apoptotic analysis using the SIAH1 siRNA whose effects were already
validated. Cleaved PARP1 and caspase 3 were observed in SBC5 cells
after treatment with siEHMT2, implying that apoptosis is likely to be
induced by the knockdown of EHMT2. Subsequently, we examined
the effects of SIAH1 knockdown on EHMT2 siRNA-induced apoptosis.
Importantly, the cleavage of PARP1 and caspase 3 was not observed in
SBC5 cells treated with both EHMT2 and SIAH1 siRNAs (Figure 5A).
These data reveal that SIAH1 is an essential factor for EHMT2 siRNA-
induced apoptosis. Furthermore, we conducted the growth assay after
treatment with siEHMT2 and either siEGFP or siSIAH1. The growth
of SBC5 cells was significantly suppressed by treatment with siEHMT2,
but the growth suppression was recovered by knockdown of SIAH1
(Figure 5B). This result was confirmed by a colony formation assay
(Figure 5C ). Taken together, our findings suggest that SIAH1 is di-
rectly regulated by EHMT2, and it seems to play a key role in regulat-
ing growth and apoptosis of cancer cells overexpressing EHMT2.
BIX-01294 Reduced the Growth Rate of Five Cancer
Cell Lines
A small molecule compound, BIX-01294 (a diazepin-quinazolin-
amine derivative), specifically inhibits EHMT2 enzymatic activity and
Figure 2. Elevated EHMT2 expression in lung cancer. (A) Comparison of EHMT2 expression between normal lung and small cell lung
cancer (SCLC) tissues. Signal intensity of each sample was analyzed by cDNA microarray, and the result is shown by box-whisker plot
(median, 50% boxed). Mann-Whitney U test was used for the statistical analysis. (B) Expression of EHMT2 in normal lung, 17 non–small
cell lung cancer (NSCLC) and 6 SCLC tissues. Expression levels were analyzed by quantitative real-time PCR. Data were normalized by
normal lung expressions. (C) mRNA expression levels of EHMT2 in two normal human cell lines and four lung cancer cell lines examined
by quantitative real-time PCR. Expression levels were normalized by GAPDH and SDH expressions, and values are relative to CCD-18Co
(CCD-18Co = 1). (D) Immunohistochemical staining of EHMT2 in lung tissues. Clinical information for each section is represented above
histologic pictures. Original magnification, ×200.
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reduces H3K9me2 levels at the chromatin regions of several EHMT2
target genes [28,29]. Because EHMT2 may be involved in the pro-
liferation of cancer cells, we evaluated the effects of BIX-01294 on the
growth of cancer cell lines. To examine the relationship between
EHMT2 expression and BIX-01294 effects, we chose cancer cells that
showed a wide variety of EHMT2 expression levels (Figure W2A). As
shown in Figure W2B, the growth of cancer cells was significantly
suppressed by BIX-01294 treatment in a dose-dependent manner,
and the effect was correlated with EHMT2 expression levels. The cell
cycle status of SBC5 cells after treatment with BIX-01294 was exam-
ined, and the proportion of cells in the S phase significantly decreased
and that in the sub-G1 phase increased in a dose-dependent manner
(Figure W2C ). These results indicate that the enzymatic activity of
EHMT2 can be closely related to the growth of cancer cells and that
inhibition of EHMT2 may induce growth suppression and apoptosis
of cancer cells.
Discussion
Histone modifications, including methylation, acetylation, phos-
phorylation, and ubiquitination, are considered to play critical roles
in transcriptional activation and repression through the regulation
of chromatin structure. Histone methylation was once thought to
be a stable modification, but recently, it is recognized as being dynami-
cally regulated by both histone methyltransferases and demethylases.
Figure 3. Involvement of EHMT2 in the growth of bladder and lung cancer cells. (A) Expression levels of EHMT2 in various cell lines.Western
blot was performed to measure the protein level of EHMT2, and anti-ACTB antibody was used as an internal control. (B) Quantitative real-
time PCR analysis showing suppression of endogenous expression of EHMT2 by EHMT2-specific siRNAs (siEHMT2 #1 and #2) in A549
and SBC5 cells. siEGFP and siNC were used as controls. Relative mRNA expression shows the value normalized by expression levels of
siEGFP-treated cells. Mean ± SD of three independent experiments. P values were calculated using Student’s t test (**P < .01; ***P <
.001). (C) Effects of EHMT2 siRNAs knockdown on the viability of bladder cancer cell line (SW780, RT4) and lung cancer cell lines (LC319,
SBC5, A549). The relative cell number shows the value normalized to siEGFP-treated cells. Mean ± SD of three independent experiments.
P values were calculated using Student’s t test (*P< .05; **P< .01; ***P< .001). (D) SW780 cells were treated with siRNAs and analyzed
by FACS 72 hours after siRNA treatment. We show representative histograms of this experiment. Numerical analysis of the FACS result,
classifying cells by cell cycle status. The proportion of cancer cells in sub-G1 phase is significantly higher after treatment with siEHMT2 #1
and #2 compared with control siRNAs-treated cancer cells. Mean ± SD of three independent experiments. P values were calculated using
Student’s t test.
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EHMT2 is mainly responsible for monomethylation and dimethylation
of H3K9 in euchromatin, and these play a unique role in transcriptional
regulation and chromatin remodeling [11–13,30,31]. In this study,
we demonstrated the significant up-regulation of EHMT2 in bladder
and lung cancers by quantitative RT-PCR and immunohistochemistry
at the RNA and protein levels. Together with microarray-based ex-
pression profiles of a large number of clinical tissues, EHMT2 expres-
sion is considered to be dysregulated in nine human tumors (Table 1).
We postulated that EHMT2may serve an important role in the growth
regulation of cancer cells and confirmed that knockdown of EHMT2
suppresses the growth of various bladder and lung cancer cells, with
the number of cells in the sub-G1 phase increasing (Figure 3, C and
D). The pathway analysis using the cells in which EHMT2 expression
was knocked down by siRNA indicated that EHMT2 could be in-
volved in the regulation of cell apoptosis and a variety of chromatin
functions such as chromatin remodeling and transcriptional regulation
(Table W3).
It has been suggested that SIAH1 is a tumor suppressor gene located
in chromosomal band 16q12-q13, a frequently deleted region in human
tumors arising from various tissues [32,33]. It was also reported that E3
ubiquitin ligases, including SIAH1, played an important role in regulat-
ing breast carcinogenesis [34], and a recent study indicated that SIAH1
Figure 4. SIAH1 expression was directly regulated by EHMT2. (A) Two-dimensional, unsupervised hierarchical cluster analysis of SW780
and A549 cells after knockdown of EHMT2 expression. Differentially expressed genes were selected for this analysis. Red indicates up-
regulated; green, downregulated. (B) Graph of microarray result (left) and validation of microarray data using quantitative real-time PCR
(right) in A549 cells after treatment with siRNAs targeting EGFP (control; siEGFP) and EHMT2 (siEHMT2 #2). P values were calculated using
Student’s t test (**P < .01; ***P < .001). (C) Western blot analyses in A549 cells after treatment with siRNAs targeting EGFP (control;
siEGFP) and EHMT2 (siEHMT2 #2). Samples were fractionated by SDS-PAGE and immunoblotted with anti-EHMT2 (NB100-40825; Novus
Biologicals) and -SIAH1 (sc-5506; Santa Cruz, Santa Cruz, CA) antibodies. Anti-ACTB was used as an internal control. (D) The ChIP assay
was performed using anti-FLAG and -H3K9me2 antibodies after transfection with pCAGGSn-3FC (Mock) and pCAGGSn-3FC-EHMT2
(3×FLAG-EHMT2) into 293T cells. Top left: Schematic diagram of the SIAH1 promoter region. The PCR amplified fragment is positioned
by nucleotide number relatives to TSS (arrows). Bottom left: Real-time PCR analysis using a primer pair as described under Materials and
Methods. Cross-linked and sheared chromatin was immunoprecipitated with anti-FLAG antibody (M2; Sigma). The result is shown as a
percentage of the input chromatin. Top right: Input samples were fractionated by SDS-PAGE and immunoblotted with anti-FLAG antibody.
Expression of ACTB was the internal control. Bottom right: Quantification of H3K9me2 ChIP at the SIAH1 promoter region using real-time
PCR. Cross-linked and sheared chromatin was immunoprecipitated with anti-H3K9me2 antibody (ab1220; Abcam, Cambridge, MA). (E) The
ChIP assay was performed using anti-EHMT2 (bottom left) and -H3K9me2 (bottom right) antibodies after treatment of SBC5 cells with
siEGFP or siEHMT2 #2 for 48 hours. The result is shown as a percentage of the input chromatin. Top: Input samples were fractionated
by SDS-PAGE and immunoblotted with anti-EHMT2 antibody. Expression of ACTB was the internal control.
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induces apoptosis by activating the JNK pathway and inhibits invasion
by inactivating the ERK pathway in breast cancer cells [22]. We previ-
ously reported that the paternally expressed gene 10 (PEG10), which
was highly expressed in hepatocellular carcinomas, associated with
SIAH1 and PEG10 overexpression decreased the cell death mediated
by SIAH1 [20]. Moreover, our expression profile data show that the
expression levels of SIAH1 in tumor tissues are significantly low com-
pared with the corresponding nonneoplastic tissues in various types
of cancer, including bladder and lung cancers (Table W4). These data
reveal that SIAH1 is one of the key regulators in human carcinogenesis.
Our microarray data showed that SIAH1 was upregulated by EHMT2
knockdown, and we confirmed this elevation using quantitative real-
time PCR and Western blot analyses. In addition, we found that
EHMT2 directly binds to the promoter region of SIAH1 and regulates
the transcription of SIAH1 through the histone methylation analyzed
by ChIP assay (Figure 4, D and E). Consistently, the apoptosis induc-
tion and growth suppression after treatment with EHMT2 siRNA was
recovered by SIAH1 knockdown (Figure 5). According to our series
of experiments, EHMT2 directly regulates SIAH1 expression through
methylation of histone H3-K9, and it may be an important mechanism
on how overexpressed EHMT2 contributes to human carcinogenesis.
In the present study, we found that EHMT2 was overexpressed in
various types of cancer, including bladder and lung cancers, and plays a
crucial role in the proliferation of cancer cells. Importantly, the BioGPS
database revealed that the expression of EHMT2 in many types of
normal tissues is very low (Figure W3), indicating that EHMT2 can
be an ideal target for cancer therapy. Indeed, we evaluated the effects
of treatment with BIX-01294, a specific inhibitor of EHMT2, and
found that this chemical compound effectively suppressed the growth
of cancer cells (Figure W2). This result suggests the possibility that
EHMT2 inhibitors may work as anticancer drugs. Intriguingly, it
was previously reported that down-regulation of EHMT2 disrupted
centrosome and chromosome stability in cancer cells, and cancer cell
growth was significantly inhibited [30]. The data are consistent with
our series of experiments, and inhibition of EHMT2 functions seems
to be an effective tool for cancer therapy. Meanwhile, information
about specificity and toxicity of BIX-01294 is largely insufficient. Fur-
ther validation with functional analyses of this protein in the context of
human carcinogenesis and optimization of EHMT2 inhibitors as anti-
cancer drugs may assist to development of novel therapeutic strategies
for human cancer.
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Supplemental Data
Materials and Methods
Tissue samples and RNA preparation. Bladder tissue samples and
RNA preparation were described previously [1]. Briefly, 126 surgical
specimens of primary urothelial carcinoma were collected, either at
cystectomy or at transurethral resection of bladder tumor (TUR-Bt)
and snap-frozen in liquid nitrogen. A total of 26 normal bladder tissues
were collected from areas of macroscopically normal regions in patients
with no evidence of malignancy. Five sequential sections of 7-μm thick-
ness were cut from each tissue and stained using Histogene staining
solution (Arcturus, Oxnard, CA) following the manufacturer’s protocol
and assessed for cellularity and tumor grade by an independent con-
sultant urohistopathologist. Approximately 10,000 cells were micro-
dissected from both stromal and epithelial/tumor compartments in
each tissue. To validate the accuracy of microdissection, primers and
probes for Vimentin and Uroplakin were sourced and quantitative
RT-PCR was performed according to the manufacturer’s instructions
(Assays-on-Demand; Applied Biosystems). Vimentin is primarily ex-
pressed in mesenchymally derived cells and used as a stromal marker.
Uroplakin is a marker of urothelial differentiation and is preserved in
up to 90% of epithelially derived tumors [2]. Use of tissues for this study
was approved by Cambridge shire Local Research Ethics Committee
(ref. 03/018).
Expression profiling in cancers using cDNA microarrays. We
established a genome-wide cDNA microarray with 36,864 cDNAs or
ESTs selected from the UniGene database of the National Center for
Biotechnology Information. This microarray system was constructed
essentially as described previously [3-5]. Briefly, the cDNAs were
amplified by RT-PCR using poly(A)+ RNAs isolated from various
human organs as templates; the lengths of the amplicons ranged from
200 to 1100 bp, without any repetitive or poly(A) sequences. Many
types of tumors and corresponding nonneoplastic tissues were pre-
pared in 8-μm sections, as described previously [4]. A total of 30,000
to 40,000 cancer or noncancerous cells were collected selectively using
the EZ cut system (SL Microtest GmbH, Jena, Germany) according
to the manufacturer’s protocol. Extraction of total RNA, T7-based
amplification, and labeling of probes were performed as described pre-
viously [4]. Aliquots (2.5 μg) of twice-amplified RNA (aRNA) from
each cancerous and noncancerous tissue were then labeled, respectively,
with Cy3-dCTP or Cy5-dCTP. Detailed expression profiling data of
bladder and lung cancers, shown in this study, were based on the data
reported previously by Drs Ryo Takata and Takefumi Kikuchi, respec-
tively [3,6].
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Table W1. Clinicopathologic Characteristics and EHMT2 Expression.
Tissue Sample Name EHMT2 Stage Grade
Tumor BT2 38.154 T4 3
BT5 7.597 Ta
BT6 2.488 Ta 2
BT8 0.809 Ta 2
BT9 0.021 Ta 2
BT10 9.196 T2 3
BT15 3.718 T2 3
BT16 2.943 Ta 2
BT18 8.825 Ta 3
BT20 0.305 T1 2
BT21 4.680 Ta 3
BT22 18.100 T2 2
BT23 7.790 T1 2
BT27 2.243 T3 3
BT28 22.929 Ta 1
BT31 7.520 Ta 2
BT32 1.898 T2 3
BT33 2.310 T1 2
BT34 2.800 Ta 2
BT36 0.963 T2 3
BT38 7.842 Ta 2
BT39 0.302 T1 3
BT40 1.259 T2 3
BT41 0.633 T1 2
BT42 0.644 T2 3
BT43 2.295 Ta 1
BT44 0.481 T1 2
BT46 4.627 Ta 2
BT48 8.698 T2 3
BT49 5.598 Ta 1
BT50 10.781 T1 3
BT51 31.680 Ta 2
BT52 2.046 T3 3
BT53 9.685 Ta 2
BT54 0.722 T1 3
BT56 16.182 T2 3
BT57 1.752 T1 2
BT58 9.347 Ta 2
BT59 0.662 T2 3
BT60 3.617 Mets 3
BT64 1.602 Ta 2
BT66 2.831 Ta 1
BT67 0.402 T1 2
BT68 4.220 Ta 2
BT69 10.400 Ta 2
BT70 3.590 T1 2
BT71 2.750 T1 3
BT72 27.900 Ta 1
BT74 12.300 Ta 1
BT76 2.730 T1 1
BT77 4.420 Ta 2
BT78 1.629 T1 3
BT79 0.921 Ta 2
BT80 2.485 Ta 2
BT81 2.243 Ta 2
BT82 1.629 T1 3
BT83 0.921 Ta 2
BT84 27.809 Ta 2
BT85 1.874 T1 2
BT87 2.045 T2 2
BT88 12.620 T1 3
BT90 4.001 Ta 2
BT92 3.184 T1 2
BT93 1.557 T2 3
BT94 3.563 Ta 1
BT95 1.111 T3a 3
BT96 2.485 Ta 1
BT97 0.192 Ta 2
BT98 2.121 Ta 2
BT99 2.078 T1 2
BT100 53.775 T1 3
BT101 5.750 T2 3
BT103 3.240 T1 2
Table W1. (continued ).
Tissue Sample Name EHMT2 Stage Grade
BT105 0.514 T2 2
BT106 1.300 Ta 3
BT107 1.570 Mets 3
BT108 0.027 T1 2
BT109 27.900 Ta 2
BT110 0.703 T1 2
BT112 92.800 Ta 3
BT113 0.984 T1 3
BT114 1.910 T2 3
BT115 1.800 T1 3
BT116 2.160 T2a 3
BT119 0.788 Ta 2
BT120 2.670 Ta 2
BT122 1.980 T1 3
BT125 1.970 T1 2
BT127 9.672 T1 2
BT128 6.160 Ta 1
BT129 0.576 Ta 2
BT130 7.240 Ta 2
BT131 1.574 T2 3
BT132 0.908 T2 3
BT133 1.367 T1 2
BT135 1.419 T2 3
BT137 0.221 Ta 2
BT138 2.925 Ta 1
BT139 1.194 T2 3
BT140 5.000 Ta 2
BT141 1.310 Mets 3
BT143 1.550 T1 3
BT145 1.320 T2 2
BT150 0.854 Ta 2
BT151 0.964 Ta 3
BT152 10.261 Ta 2
BT154 3.450 T1 3
BT158 10.420 Ta 2
BT160 0.780 T1 2
BT161 3.190 Ta 2
BT164 1.477 Ta 1
BT169 5.186 T2 3
BT178 2.940 Ta 2
BT180 0.955 T1 2
BT181 0.749 T2 3
BT187 2.364 Ta 2
BT188 18.595 T2 3
BT189 4.517 T1 2
Normal BN11A 1.142 Normal Normal
BN11B 1.494 Normal Normal
BN12A 1.858 Normal Normal
BN13A 0.601 Normal Normal
BN13B 0.962 Normal Normal
BN14A 1.216 Normal Normal
BN14B 0.677 Normal Normal
BN15A 0.693 Normal Normal
BN17B 0.533 Normal Normal
BN18 3.260 Normal Normal
BN18B 9.540 Normal Normal
BN19A 0.765 Normal Normal
BN1A 0.863 Normal Normal
BN20B 0.900 Normal Normal
BN21A 0.955 Normal Normal
BN22A 1.157 Normal Normal
BN22B 0.876 Normal Normal
BN24B 0.881 Normal Normal
BN25A 0.765 Normal Normal
BN26A 1.350 Normal Normal
BN2A 1.840 Normal Normal
BN2B 1.091 Normal Normal
BN4A 1.151 Normal Normal
BN4B 0.835 Normal Normal
BN5B 0.610 Normal Normal
BN6A 1.094 Normal Normal
BN8A 0.891 Normal Normal
BN9A 0.889 Normal Normal
Table W2. siRNA Sequence.
siRNA Name Sequence
siEGFP Sense: 5′ GCAGCACGACUUCUUCAAGTT 3′
Antisense: 5′ CUUGAAGAAGUCGUGCUGCTT 3′
siFFLuc Sense: 5′ GUGCGCUGCUGGUGCCAACTT 3′
Antisense: 5′ GUUGGCACCAGCAGCGCACTT 3′
siNegative control
(cocktail)
Target #1 Sense: 5′ AUCCGCGCGAUAGUACGUA 3′
Antisense: 5′ UACGUACUAUCGCGCGGAU 3′
Target #2 Sense: 5′ UUACGCGUAGCGUAAUACG 3′
Antisense: 5′ CGUAUUACGCUACGCGUAA 3′
Target #3 Sense: 5′ UAUUCGCGCGUAUAGCGGU 3′
Antisense: 5′ ACCGCUAUACGCGCGAAUA 3′
siEHMT2 #1 Sense: 5′ GAGUUUGGCUAUGAGGCUATT 3′
Antisense: 5′ UAGCCUCAUAGCCAAACUCTT 3′
siEHMT2 #2 Sense: 5′ GCAAAUAUUUCACCUGCCATT 3′
Antisense: 5′ UGGCAGGUGAAAUAUUUGCTT 3′
siSIAH1 Sense: 5′ CGAUUGACUUGGGAAGCGATT 3′
Antisense: 5′ UCGCUUCCCAAGUCAAUCGTT 3′
Table W3. Gene Ontology Pathway Analysis Based on the Affymetrix’s Microarray Data.
Entry ID Name Definition P
GO0003677 DNA binding Interacting selectively with DNA (deoxyribonucleic acid). 4.7 × 10−6
GO0045449 Regulation of transcription Any process that modulates the frequency, rate, or extent of the synthesis of either RNA on a template of DNA
or DNA on a template of RNA.
4.0 × 10−6
GO0051726 Regulation of cell cycle Any process that modulates the rate or extent of progression through the cell cycle. 3.0 × 10−6
GO0006355 Regulation of transcription, DNA-dependent Any process that modulates the frequency, rate, or extent of DNA-dependent transcription. 3.2 × 10−5
GO0004605 Phosphatidate cytidylyltransferase activity Catalysis of the reaction: CTP + phosphatidate = diphosphate + CDP-diacylglycerol. 9.7 × 10−4
GO0031570 DNA integrity checkpoint Any cell cycle checkpoint that delays or arrests cell cycle progression in response to changes in DNA structure. 8.5 × 10−4
GO0000075 Cell cycle checkpoint A point in the eukaryotic cell cycle where progress through the cycle can be halted until conditions are suitable
for the cell to proceed to the next stage.
5.8 × 10−4
GO0051338 Regulation of transferase activity Any process that modulates the frequency, rate, or extent of transferase activity, the catalysis of the transfer
of a group, e.g., a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from
one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor).
Transferase is the systematic name for any enzyme of EC class 2.
3.6 × 10−4
GO0016481 Negative regulation of transcription Any process that stops, prevents, or reduces the frequency, rate, or extent of transcription. 2.2 × 10−4
GO0000278 Mitotic cell cycle Progression through the phases of the mitotic cell cycle, the most common eukaryotic cell cycle, which canonically
comprises four successive phases called G1, S, G2, and M and includes replication of the genome and the
subsequent segregation of chromosomes into daughter cells. In some variant cell cycles, nuclear replication
or nuclear division may not be followed by cell division, or G1 and G2 phases may be absent.
1.6 × 10−4
GO0016564 Transcription repressor activity Any transcription regulator activity that prevents or downregulates transcription. 1.4 × 10−4
GO0007346 Regulation of mitotic cell cycle Any process that modulates the rate or extent of progress through the mitotic cell cycle. 3.6 × 10−3
GO0045892 Negative regulation of transcription,
DNA-dependent
Any process that stops, prevents, or reduces the frequency, rate, or extent of DNA-dependent transcription. 3.4 × 10−3
GO0016568 Chromatin modification The alteration of DNA or protein in chromatin, which may result in changing the chromatin structure. 2.5 × 10−3
GO0008629 Induction of apoptosis by intracellular signals Any process induced by intracellular signals that directly activates any of the steps required for cell death
by apoptosis.
2.2 × 10−3
GO0006281 DNA repair The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents
in the environment and by free radicals or alkylating agents endogenously generated in metabolism. DNA is
also damaged because of errors during its replication. A variety of different DNA repair pathways have been
reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass,
double-strand break repair pathway, and mismatch repair pathway.
1.52 × 10−3
GO0007093 Mitotic cell cycle checkpoint A signal transduction–based surveillance mechanism that ensures accurate chromosome replication and segregation
by preventing progression through a mitotic cell cycle until conditions are suitable for the cell to proceed to the
next stage.
1.05 × 10−3
GO0006350 Transcription The synthesis of either RNA on a template of DNA or DNA on a template of RNA. 1.02 × 10−3
GO0006917 Induction of apoptosis A process that directly activates any of the steps required for cell death by apoptosis. 4.2 × 10−2
GO0043065 Positive regulation of apoptosis Any process that activates or increases the frequency, rate, or extent of cell death by apoptosis. 4.2 × 10−2
GO0008624 Induction of apoptosis by extracellular signals Any process that activates or increases the frequency, rate, or extent of cell death by apoptosis. 2.2 × 10−2
Table W4. Expression of SIAH1 in Cancer Tissues Analyzed by cDNA Microarray*.
Tissue Type Case (n) Ratio (Tumor/Normal)
Count < 1/2 Count < 1/3 Count < 1/5 Count < 1/10
Bladder cancer 33 19 (57.5%) 17 (51.5%) 15 (45.4%) 11 (33.3%)
Breast cancer 41 27 (65.8%) 23 (56.0%) 16 (39.0%) 9 (21.9%)
Cholangiocellular carcinoma 25 17 (68.0%) 14 (56.0%) 12 (48.0%) 11 (44.0%)
Non–small cell lung cancer 26 16 (61.5%) 14 (53.8%) 11 (42.3%) 9 (34.6%)
Prostate cancer 50 22 (44.0%) 18 (36.0%) 15 (30.0%) 4 (8.0%)
Small cell lung cancer 15 11 (73.3%) 7 (46.6%) 1 (6.6%) 0 (0.0%)
*We compared the signal intensity of SIAH1 between tumor tissues and corresponding nonneoplastic tissues derived from the same patient.
Table W5. Primer Sequences for Quantitative RT-PCR and ChIP Analyses.
Gene Name Primer Sequence
GAPDH (housekeeping gene)- f 5′ GCAAATTCCATGGCACCGTC 3′
GAPDH (housekeeping gene)- r 5′ TCGCCCCACTTGATTTTGG 3′
SDH (housekeeping gene)- f 5′ TGGGAACAAGAGGGCATCTG 3′
SDH (housekeeping gene)- r 5′ CCACCACTGCATCAAATTCATG 3′
EHMT2- f1 5′ GGAGGAAGCTGAACTCAGGAGG 3′
EHMT2- r1 5′ GACTGAAGTCATCACCCACCAC 3′
SIAH1- f1 5′ GTTACCGCCCATTCTTCAAT 3′
SIAH1- r1 5′ GACAACATGTGAGCTTTGGG 3′
SIAH1-ChIP- f1 5′ AGCAACGGTAGCCGAGTAG 3′
SIAH1-ChIP- r1 5′ TGGCCGCCGCCGCCGCCGTTTCGC 3′
Figure W1. Expression of EHMT2 in 2 normal cell lines, 12 bladder
cancer cell lines, and 5 lung cancer cell lines. Expression levels of
EHMT2 were analyzed by quantitative real-time PCR. Data were
normalized by GAPDH and SDH expressions.
Figure W2. BIX-01294 reduces growth rate in five cancer cell lines. (A) Expression levels of EHMT2 in five cancer cells analyzed by
quantitative real-time PCR. (B) Effect of BIX-01294 on the viability of cancer cell lines. Cancer cell lines were treated for 2 days with
the inhibitor BIX-01294 (2, 4, and 6 μM). This result was normalized by negative control (NC); pure water. Statistical analysis was done
based on three independent experiments. P values were calculated using Student’s t test. (C) Cell cycle distribution was analyzed by
flow cytometry after coupled staining with fluorescein isothiocyanate (FITC)–conjugated anti-BrdU and 7-amino-actinomycin D (7-AAD)
as described in Materials and Methods.
Figure W3. Expression levels of EHMT2 in 78 normal tissues. Data were derived from BioGPS (http://biogps.gnf.org/#goto=welcome).
GAPDH expression is shown as a control of the signal intensity.
